Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Foundation Medicine’s lead product, a cancer diagnostic called FoundationOne, could help drive new business for drug makers like GlaxoSmithKline (NYSE: GSK) and Roche AG’s Genentech unit, by vastly expanding the number of patients who can take their drugs. The privately-held Cambridge, Mass.-based company’s test has detected HER2 mutations in 14 different types of cancer, meaning that the drugs approved to do battle with this mutation could benefit many more patients. Typically only patients with breast cancer and gastro-esophageal cancer are screened for this mutation, and these are the only indications for which drugs targeting HER2 are approved.
Help employers find you! Check out all the jobs and post your resume.
